+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acadia Pharmaceuticals Inc - logo

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.

From
From
From
Global Parkinson's Drug Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Parkinson's Drug Market & Clinical Trial Insight 2025

  • Clinical Trials
  • January 2020
  • 500 Pages
From
Antipsychotic Drugs: Technologies and Global Markets - Product Thumbnail Image

Antipsychotic Drugs: Technologies and Global Markets

  • Report
  • September 2018
  • 174 Pages
From
From
From
From
Drug Overview: Nuplazid - Product Thumbnail Image

Drug Overview: Nuplazid

  • Report
  • March 2018
  • 16 pages
From
Schizophrenia - Pipeline Review, H2 2020 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 440 pages
From
From
From
From
From
From
Loading Indicator
adroll